The penetration of piperacillin-tazobactam in eight mechanically ventilated intensive care patients (age, 56.0 12.2 years, and weight, 76.5 15.2 kg [means standard deviations]) with bacterial pneumonia was investigated. They were given intravenous doses of piperacillin (4 g) and tazobactam (0.5 g) as 30-min infusions every 6 h. The kinetic study was performed after the fourth dose on day 2 of treatment. Samples of blood and bronchial secretions (BS) were collected before the fourth dosing and 0.5, 1, 2, 4, and 6 h after the end of infusion. Drug concentrations in both sera and BS were measured by high-performance liquid chromatography. Concentrations 
The clinical outcome of bacterial respiratory tract infections is a function of two factots: the efficacy of the host defense mechanisms and institution of adequate antimicrobial therapy. The latter parameter includes obtaining appropriate concentrations of antibacterial agents at the site of infection, i.e., concentrations that at least equal or best exceed the MICs of the antimicrobial agent for the responsible pathogens. If the antimicrobial therapy includes a ,B-lactamase inhibitor, its concentrations at the site of infection must at least equal those required to inhibit most of the susceptible 1-lactamases and thus to convert beta-lactam-resistant strains into susceptible ones. This is a prerequisite; nevertheless, up to now there has been no way to know how high the concentrations must be for optimum inhibitory activity or how long they should stay above a certain concentration.
Tazobactam is a new penicillanic acid sulfone derivative acting as a potent 1-lactamase inhibitor. In combination with piperacillin, it provides a broad spectrum of activity against numerous ,B-lactamase-producing organisms, including anaerobes (7, 15) .
One of the ways to evaluate the therapeutic value of this new combination in the treatment of respiratory tract infections is to measure what concentrations of both agents are achievable at different sites of the respiratory tree after the usual regimen of dosage. Bronchial secretions are from one of these different relevant sites, as are bronchial mucosa, bronchoalveolar lavage samples, and certainly others.
Whereas the penetration of piperacillin into bronchial secretions has been documented, no data concerning that of tazobactam are currently available. The purpose of the present study was to define the penetration of piperacillin and tazobac-tam into the bronchial secretions of intensive care patients after multiple doses of 4.5 g of the combination (4 g of piperacillin and 0.5 g of tazobactam).
( Table 1 . Before inclusion of the patients in the study, the pneumonia was assessed by a bronchial brushing and a protected distal aspiration. Gram staining of the aspiration sample gave evidence of the gramnegative bacilli responsible for the nosocomial pneumonia. A bacterial count of >103 CFU/ml in the bronchial brushing sample confirmed the diagnosis. All the patients were intubated and mechanically ventilated. The severity of the pneumonia was assessed by the Apache II score (12) , as indicated in Table 1 . All patients received piperacillin (4 g) and tazobactam (0.5 g) every 6 h in a single syringe as a 30-min infusion. The associated antimicrobial agents were an aminoglycoside in all cases (netromycin or amikacin) plus pefloxacin (patient 5), fluconazole (patient 6), or vancomycin (patients 7 and 8). None of these associated drugs is known to cause a potential pharmacokinetic interaction with either piperacillin or tazobactam or their combination (9) . The creatinine clearance was determined from the 24-h urine samples.
Study procedure. The pharmacokinetic study was performed on day 2 of parenteral therapy, after the fourth intravenous (i.v.) piperacillin-tazobactam dose was given. Blood samples were collected from the contralateral vein predose (0 h) and Drug analysis. Piperacillin and tazobactam concentrations in sera and bronchial secretions were measured by highperformance liquid chromatography (HPLC) as previously described (9) . Briefly, for the measurement of tazobactam in sera, 500 RI of the sample was supplemented with 10 ,u of saturated sodium monohydrogenocarbonate in a screw-cap glass tube and, after mixing, deproteinized with 50 ,ul of trifluoroacetic acid. After mixing and centrifugation (3,000 x g, 10 min), the supernatant was transferred to another tube and mixed with 1 ml of chloroform. After 15 s of vortexing and 15 min of centrifugation at 3,000 x g, the supernatant was kept in ice until the HPLC analysis. Before the tazobactam in the bronchial secretions was measured, the samples were predigested with an equivalent volume of a solution of 2,3-dihydroxy-1,4-dithiolbutane (Digest-EUR; Laboratory Eurobio, Paris, France). Five hundred microliters of the mixture was then treated in the same manner as the sera.
For the mobile phase of the HPLC analysis of tazobactam, a solution of 80 mM phosphate buffer (pH 6.5) containing 5% acetonitrile was used. The flow rate was 1 ml/min, and separations were performed on a high-speed C18 reversed-phase analytical column (75 by 4.6 mm) (Ultrasphere ODS; Beckman). Detection was by UV A214. Under these conditions, the retention time of tazobactam was 2.6 min.
For piperacillin, 500 pAl of serum was deproteinized with 500
pl of acetonitrile in a screw-cap glass tube. After mixing and centrifugation (3,000 x g, 10 min), the supematant was transferred to another screw-cap glass tube and mixed with 3.5 ml of methylene chloride. After mixing (10 min, 20 rpm) and centrifugation (3,000 x g, 10 min), the final supernatant was used for the HPLC analysis of piperacillin. The measurement of piperacillin in the bronchial secretions was performed in the same manner as that for sera after a predigestion of the samples by an equal volume of 2,3-dihydroxy-1,4-dithiolbutane. For the mobile phase, a solution of 20 mM ammonium acetate adjusted to pH 5 with acetic acid and containing 24% acetonitrile was used. The separations were performed on the same type of analytical column as that used for tazobactam at a flow rate of 1 ml/min. Detection was performed at 214 nm. Under these conditions, the retention time of piperacillin was 4.3 min.
For both drugs, the analytical procedures were validated by control of precision, accuracy, recovery, and limits of detection. Precision was assessed by investigating the within-and between-day reproducibilities in sera as well as in bronchial secretions at both low and high concentrations for both drugs (low and high concentrations of piperacillin and tazobactam in sera, 5 and 200 jg/ml and 1 and 50 p,g/ml, respectively; low and high concentrations of piperacillin and tazobactam in bron- Table 2 and Fig. 1 . The mean piperacillin/tazobactam concentration ratio in sera during the investigational period was 9.01 ± 0.9, whereas that obtained for bronchial secretions was 5.67 ± 1.23 (Table 3 ). The mean pharmacokinetic parameters are shown in Table 4 .
There is a relatively good homogeneity in the AUCpipser/ AUCtazser ratios ranging from 6 Regarding the absolute concentrations of piperacillin in both plasma and bronchial secretions, it is interesting to note that they are above the lower breakpoint (8 ,ug/ml in France) defining the susceptibility of pathogens to piperacillin during the complete interval between two administrations.
The serum pharmacokinetic profiles of piperacillin and tazobactam parallel each other very well. In most of the blood samples from all patients, the piperacillin/tazobactam concentration ratios are quite near 8, i.e., identical to the ratio of the administered formula. The mean concentration ratios of piperacillin and tazobactam (Table 3 ) range from 8.06 (0.5 h after the end of infusion) to 10.3 (4 h after the end of infusion). The mean ratio (9.01 ± 0.9) is equivalent to the mean of the AUCpip serAUCtaz.ser ratio, which is 8.45 ± 1.62. These data are in good agreement with previously published data (8-10, 13, 14 
